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HospitalisationBackground: An adjuvanted herpes zoster (HZ) subunit vaccine, HZ/su, demonstrated high efficacy
against HZ and postherpetic neuralgia (PHN) in two randomized, observer-blind, placebo-controlled trials
in adults aged 50 and 70 years (ZOE-50 and ZOE-70, respectively).
Methods: Data from ZOE-50 and ZOE-70 trials were analyzed to evaluate the efficacy of HZ/su against
mortality, hospitalizations, and non-PHN complications of HZ including HZ-associated vasculitis, stroke,
and disseminated, ophthalmic, neurologic, and visceral diseases.
Results: In the pooled ZOE-50/ZOE-70 analysis, 1 of 32 HZ/su recipients (3.1%) and 16 of 477 placebo
recipients (3.4%) with a confirmed HZ episode had complications other than PHN. Efficacy against
HZ-related complications was 93.7% (95% confidence interval, 59.5–99.9%) in adults aged 50 years
and 91.6% (43.3–99.8%) in adults 70 years. Five HZ-related hospitalizations, all in placebo recipients,
and no HZ-related deaths were reported.
Conclusions: HZ/su reduces the risk of HZ-associated complications in older adults (NCT01165177;
NCT01165229).
 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Herpes zoster (HZ) results from the reactivation of latent
varicella-zoster virus (VZV) in sensory ganglia, typically years after
primary infection [1,2]. The most common complication of HZ,
postherpetic neuralgia (PHN), is a chronic neuropathic pain that
persists after resolution of the HZ rash [2,3]. In adults aged
50 years, the risk of developing PHN can be >30% [4]. Other HZ
complications include disseminated HZ, and neurological, visceral,
or vascular diseases, including stroke [1,4–6]. HZ ophthalmicus
occurs when VZV reactivation affects the ophthalmic branch of
the fifth cranial nerve and can involve eye structures (hereafter
referred to as ophthalmic disease) [7]. The risk of HZ ophthalmicus
among HZ patients ranges between 10% and 15%, with ophthalmic
disease in approximately 30–80% of these cases [4,8]. The inci-
dence, severity, and duration of PHN and other HZ complications
generally increase with age [4].
1538 M. Kovac et al. / Vaccine 36 (2018) 1537–1541In two phase 3 clinical trials, a HZ subunit vaccine (HZ/su), con-
taining recombinant VZV glycoprotein E and the AS01B Adjuvant
System, was highly efficacious in preventing HZ and PHN in older
adults [9,10]. Here, we report the efficacy of HZ/su in preventing
HZ-associated complications, hospitalizations, and deaths.2. Methods
2.1. Study design and participants
ZOE-50 (Clinicaltrials.gov, NCT01165177) and ZOE-70
(NCT01165229) were randomized, observer-blind, placebo-
controlled, phase 3 studies conducted concurrently in 18 countries
in Europe, North America, Latin America, and Asia-Australia [9,10].
Adults aged 50 years (ZOE-50) or 70 years (ZOE-70) received
two doses of HZ/su (Shingrix, GSK) or placebo intramuscularly at
months 0 and 2. The design and results of both studies have been
previously published [9,10].2.2. Study objectives
The primary objectives were to assess HZ/su efficacy against HZ
(ZOE-50 and ZOE-70) and PHN (ZOE-70) [9,10]. The secondary and
exploratory objectives of each study described here included HZ/su
efficacy in reducing HZ-associated complications and efficacy in
reducing HZ-related mortality and hospitalizations.2.3. Assessment of HZ and PHN cases
Subject-reported suspected HZ cases were confirmed by poly-
merase chain reaction or by an ascertainment committee, as previ-
ously described [9,10]. PHN was defined as a ‘worst pain’ score 3
persisting or developing more than 90 days after the onset of HZ
rash, based on item #3 of the Zoster Brief Pain Inventory question-
naire [10,11].2.4. Herpes zoster complications
The following complications of suspected HZ cases were
recorded by the investigators as adverse events or serious adverse
events, as appropriate: HZ vasculitis; disseminated HZ; oph-
thalmic, neurologic, or visceral disease; and stroke (definitions in
Table 1). In the analysis, these events were considered complica-
tions of HZ only if they were associated with a confirmed HZ case.Table 1
Definition of herpes zoster complications.
HZ complication Definition
Disseminated disease Defined as 6 HZ lesions outside the primary dermatome as
Ophthalmic disease Defined as HZ affecting any eye structure as per investigator
Neurologic disease Defined as cranial or peripheral nerve palsies, myelitis, menin
and, in the opinion of the investigator, directly caused by VZ
Visceral disease Defined as an abnormality of one or more internal organs (e.g.
HZ and, in the opinion of the investigator, directly caused by
HZ vasculitis Vasculopathy or vasculitis (based on clinical, laboratory, or rad
opinion of the investigator, directly caused by VZV infection
Stroke A diagnosis of stroke required that criteria 1, 2, and 3 or crite
associated with an episode of HZ
Criterion 1: Rapid onset of localizing neurological deficit and
Criterion 2: Localizing neurological deficit or change in level
Criterion 3: No other cerebral process, peripheral lesion, or ot
consciousness
Criterion 4: CT or MRI scan evidence of an acute thrombotic
CT, computed tomography; HZ, herpes zoster; MRI, magnetic resonance imaging; VZV, v2.5. Statistical analysis
All analyses were performed in the modified vaccinated cohort
[9,10], which excluded participants who did not receive the second
dose or who had a confirmed HZ episode within 30 days after the
second dose.
In both studies, the incidence of HZ-associated complications in
participants with confirmed HZ (overall and by age group) was
compared between HZ/su and placebo recipients using the asymp-
totic standardized unconditional binomial test [12]. The analysis
was stratified by age group and weighted according to the propor-
tion of participants in each age group. Efficacy against HZ-related
mortality and hospitalizations considered the exact inference on
the relative risk stratified for age groups and regions, conditionally
to the total number of confirmed HZ cases observed and time at
risk. This method computes an exact confidence interval (CI)
around the rate ratio (ratio of the event rates in the HZ/su versus
placebo group) and takes into account the follow-up duration of
the subjects within each group. Vaccine efficacy was defined as 1
minus the rate ratio. HZ/su efficacy against HZ-associated compli-
cations or against mortality and hospitalizations was demon-
strated if the lower limit of the two-sided 95% CI was greater
than 0%.
The low number of confirmed HZ cases in the HZ/su group in
each study limited the power of the analyses. Therefore, a post-
hoc analysis was performed to assess efficacy in reducing the inci-
dence of HZ-associated complications (exclusive and inclusive of
PHN) in the combined ZOE-50/ZOE-70 study population, both for
participants aged 50 years and 70 years.
All significance tests were two-tailed. P-values of 0.05 were
considered to indicate statistical significance. All statistical analy-
ses were performed using SAS version 9.3 (SAS Institute) and Stat-
Xact 9.0 (Cytel) procedure for SAS.
3. Results
3.1. Study population
ZOE-50 and ZOE-70 enrolled 15,411 and 13,900 evaluable par-
ticipants, respectively [9,10]. Since publication of the primary
results of ZOE-50 (which was ongoing at the time of publication
[9]), 47 additional participants had HZ episodes: 3 in the HZ/su
group and 44 in the placebo group. Therefore, during the entire
ZOE-50 study period (mean follow-up, 3.9 ± 0.7 years), 263 sub-
jects had a confirmed HZ episode: 9 in the HZ/su group and 254
in the placebo group. In ZOE-70 (mean follow-up, 3.7 ± 0.8 years),per the investigator’s judgment
’s judgment
goencephalitis, stroke, etc. that was temporally associated with an episode of HZ
V infection arising from the HZ episode
, hepatitis, pneumonitis, gastroenteritis) temporally associated with an episode of
VZV infection arising from the HZ episode
iologic findings) that was temporally associated with an episode of HZ and, in the
arising from the HZ episode
ria 1 and 4 were fulfilled, and in the opinion of the investigator was temporally
/or change in level of consciousness
of consciousness that lasted greater than 24 h
her disorder is the cause of the localizing neurological deficit or change in level of
or hemorrhagic lesion
aricella-zoster virus.
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group and 223 in the placebo group [10].
3.2. HZ/su efficacy against HZ-related complications other than PHN
In the overall ZOE-50/ZOE-70 combined population, only one
HZ-related complication, ophthalmic disease, was observed among
the 32 HZ/su recipients (3.1%) with confirmed HZ (Table 2). At least
one HZ-related complication other than PHN was reported in 16
out of 477 (3.4%) placebo recipients with a confirmed HZ episode.
The most frequently reported complication in the placebo group
was ophthalmic disease (seven participants [1.5%]), followed by
disseminated disease (six participants [1.2%]), neurologic disease
(three participants [0.6%]), and one case of vasculitis presumed to
be due to HZ (0.2%). One participant had both ophthalmic and neu-
rologic (meningitis) disease. Most HZ-related complications
occurred in participants 70 years (13/17; 76.5%). No cases of
HZ-associated visceral disease or stroke were reported in partici-
pants in either the HZ/su group or placebo group. All participants
with HZ-related complications received antiviral therapy (usually
within the first 3 days after onset) and most received pain
medication.
Excluding PHN, the HZ complication rate for placebo recipients
50 years was 0.3/1000 person-years (PY) overall and increased
with age (Table 3). HZ/su reduced the risk of HZ-related complica-Table 2
HZ-related complications (other than PHN) in participants with a confirmed HZ episode in
Complications HZ/su (N = 13,881)
Number of participants with







50–59 years 4 0
60–69 years 3 0
70–79 years 19 1
80 years 6 0
Overall 32 1
Disseminated disease
50–59 years 4 0
60–69 years 3 0
70–79 years 19 0
80 years 6 0
Overall 32 0
Neurologic disease
50–59 years 4 0
60–69 years 3 0
70–79 years 19 0
80 years 6 0
Overall 32 0
HZ vasculitis
50–59 years 4 0
60–69 years 3 0
70–79 years 19 0
80 years 6 0
Overall 32 0
Subjects with at least one HZ-related complication
50–59 years 4 0 (0)
60–69 years 3 0 (0)
70–79 years 19 1 (1)
80 years 6 0 (0)
Overall 32 1 (1)
HZ, herpes zoster; HZ/su, herpes zoster subunit vaccine; PHN, postherpetic neuralgia.
No cases of visceral disease or stroke were diagnosed in participants with a confirmed H
* The modified vaccinated cohort excluded participants who did not receive the sec
confirmed episode of herpes zoster within 1 month (30 days) after the second dose.
a All confirmed HZ episodes considered. Numbers in parentheses represent the numbtions other than PHN by 93.7% (95% CI, 59.5–99.9%; P = 0.0003) in
participants 50 years and by 91.6% (95% CI, 43.3–99.8%;
P = 0.0035) in participants 70 years.3.3. HZ/su efficacy against HZ-related complications including PHN
In the ZOE-50/ZOE-70 combined population 50 years with
confirmed HZ, PHN and other complications developed in 5 of 32
HZ/su recipients and in 58 of 477 placebo recipients (Table S1).
HZ/su reduced HZ-related complications including PHN by 91.3%
(95% CI, 78.5–97.3%; P < 0.0001) in participants 50 years and by
88.6% (95% CI, 71.2–96.5%; P < 0.0001) in those 70 years.3.4. Reduction of mortality and hospitalizations related to a confirmed
HZ episode
In ZOE-50, no deaths or hospitalizations related to a HZ episode
were reported. In ZOE-70, no HZ-related deaths or hospitalizations
were reported for participants who received HZ/su, whereas five
HZ-related hospitalizations were reported in participants who
received placebo (Table S2). These were for neurologic disease
(two participants), disseminated HZ (one participant), neurologic
and ophthalmic disease (one participant), and reaction to
codeine given for HZ pain relief (one participant). HZ/su efficacythe ZOE-50/ZOE-70 pooled population (modified vaccinated cohort)*
Placebo (N = 14,035)
at
d
Number of participants with






0.0 103 0 0.0
0.0 90 1 1.1
5.3 216 4 1.9
0.0 68 2 2.9
3.1 477 7 1.5
0.0 103 1 1.0
0.0 90 1 1.1
0.0 216 2 0.9
0.0 68 2 2.9
0.0 477 6 1.3
0.0 103 0 0.0
0.0 90 0 0.0
0.0 216 3 1.4
0.0 68 0 0.0
0.0 477 3 0.6
0.0 103 0 0.0
0.0 90 1 1.1
0.0 216 0 0.0
0.0 68 0 0.0
0.0 477 1 0.2
0.0 103 1 (1) 1.0
0.0 90 3 (3) 3.3
5.3 216 8 (9) 3.7
0.0 68 4 (4) 5.9
3.1 477 16 (17) 3.4
Z episode. Therefore, these categories are not shown in this table.
ond dose of the herpes zoster subunit vaccine (HZ/su) or placebo or who had a
er of HZ-related complications.
Table 3
HZ/su efficacy against HZ-related complications (other than PHN) in the ZOE-50/ZOE-70 pooled population (modified vaccinated cohort).































%b 95% CI P-value
By age group
50–59 years 3491 0 13,789.7 0.0 3523 1 13,941.4 0.1 100.0 3890.4; 100.0 1.0000
60–69 years 2140 0 8621.4 0.0 2166 3 8671.8 0.3 100.0 142.8; 100.0 0.2513
70–79 years 6468 1 24,437.4 0.0 6554 8 24,691.4 0.3 87.4 5.9; 99.8 0.0403
80 years 1782 0 6324.4 0.0 1792 4 6277.5 0.6 100.0 51.1; 100.0 0.1245
Total population
70 years 8250 1 30,761.7 0.0 8346 12 30,968.9 0.4 91.6 43.3; 99.8 0.0035
Overall
(50 years)
13,881 1 53,172.9 0.0 14,035 16 53,582.1 0.3 93.7 59.5; 99.9 0.0003
CI, confidence interval; HZ, herpes zoster; HZ/su, herpes zoster subunit vaccine; PHN, postherpetic neuralgia.
a Censored at the first occurrence of a confirmed HZ-related complication other than PHN.
b Vaccine efficacy was calculated by means of the Poisson method. Vaccine efficacy in each age group was adjusted for region and overall vaccine efficacy was adjusted for
age group and region. P-values were two-sided exact P-values conditional to the number of cases.
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9.9–100.0%; P = 0.0636).4. Discussion
Based on the ZOE-50/ZOE-70 pooled analysis, HZ/su efficacy
against HZ-related complications other than PHNwas 93.7% in par-
ticipants aged 50 years and 91.6% in those 70 years. These
results are consistent with the overall efficacy against HZ, which
was 97.2% (95% CI, 93.7–99.0%) in adults aged 50 years (ZOE-
50) [9] and 91.3% (95% CI, 86.8–94.5%) in adults aged 70 years
(ZOE-50/ZOE-70) [10]. This indicates that efficacy against compli-
cations other than PHN was largely driven by the prevention of
HZ in HZ/su recipients. Because the number of breakthrough HZ
cases in the HZ/su vaccinated group was small, even in the pooled
population, it is not possible to determine whether HZ/su pre-
vented complications in vaccine recipients with breakthrough
HZ. Similarly, in the ZOE-70 trial, fewer hospitalizations were seen
in the HZ/su group than in the placebo group but the difference
was not statistically significant due to the low numbers of events
in both groups. However, a limitation of our study is that some
of these analyses are post-hoc.
The large cohort of placebo recipients in these trials provided
robust estimates of the incidence of HZ complications, without
the biases inherent in population-based estimates from databases
and case series. Excluding PHN, the overall complication rate for
placebo recipients 50 years was low at 0.3/1000 PY. This repre-
sents a HZ complication rate of 3% among participants with con-
firmed HZ. The most common complications were ophthalmic
(1.5%), disseminated (1.2%) and neurologic (0.6%) diseases. When
PHN was included as a complication, the complication rate was
11%. The age-specific incidence of PHN and other HZ-related com-
plications was less common among placebo recipients in our stud-
ies than in previous studies [4,13,14]. This may be partly
attributable to the enrolment of only immunocompetent individu-
als into our trials. In addition, as HZ episodes were closely moni-
tored during the trials, a relatively high proportion of
participants with HZ likely received prompt antiviral therapy
[1,2], which may have reduced the rate of complications and
hospitalizations.
In the pooled analysis, efficacy against HZ-related complica-
tions was similar in adults aged 50 years and 70 years, indicat-
ing that efficacy did not decline with age. This was true whether or
not PHN was included in the analysis and consistent with the over-
all efficacy against HZ previously described [9,10]. In conclusion,our results indicate that vaccination with two doses of HZ/su sub-
stantially reduces the overall risk of HZ-associated complications
among adults 50 years.
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